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Dr A. Hingorani (Brooklyn, NY). BNP has been used in
many clinical scenarios, mostly in the cardiology literature. There is
not much literature except for your group looking at it in the
vascular patient. Is this just a marker saying that these patients are
in CHF when clinically they look okay?
Dr Schouten. Probably it is more than just CHF, but it’s not
quite clear yet. NT-proBNP is also elevated in patients with isch-
emia as was shown in our study by Feringa where patients with
ischemia had a significantly higher NT-proBNP. So it could be a
combination of CHF, ischemia and some other factors like renal
dysfunction, COPD and high BMI that might be responsible for
elevated NT-proBNP. In our multivariate analysis we also ad-
justed, for example, for heart failure and for renal dysfunction,
which is known to be associated with higher NT-proBNP levels.
And despite that, NT-proBNF still has an additional value. So
there must be more than just heart failure or renal dysfunction in
this.
Dr Y. Kim (Seoul, South Korea). We analyzed the NT-
proBNP with same method. As you know NT-proBNP levels
increase in patients with chronic renal failure. Andmy first question
to you is, did you exclude from your data the patients with chronic
renal failure?
Dr Schouten. No, we did not exclude those patients in thislooked in particular into the effect of renal dysfunction on the
usefulness of NT-proBNP and what we found in that study is that
in patients who have an abnormal glomerular filtration rate, ie less
than 30 ml/min, NT-proBNP does not seem to be so effective as
compared to patients with a normal or just mildly impaired renal
function.
However, if we look into the patients with low GFR into more
detail, it’s probably just a matter of increasing the threshold of
NT-proBNP. In this study, we found a cut-off value of about 300
pg/ml. If you raise that to, let’s say, about 1,000 pg/ml for
patients with low GFR, then it might still be a good predictor. But
that’s something we will have to find out with the DECRESASE
VI study, since we then have much more patients and then prob-
ably this kind of additional values will come out.
Dr Kim. My second question is, did you analyze the data of
the differences between the preoperative and the postoperative
plasma level of NT-proBNP, or did you use the absolute level of
the postoperative NT-proBNP levels?
Dr Schouten. No, we didn’t have the postoperative levels of
NT-proBNP. We only had the preoperative levels of NT-proBNP.
Dr Kim. Do you think the difference can give more ability to
predict the cardiac event?
Dr Schouten. Well, it might be. But the point is that if you
want to predict the cardiac risk preoperatively, it’s not useful to
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DrK. Soundararajan (Philadelphia, PA). The real purpose of
your study, as I understand it, would be to use this risk stratifica-
tion and optimize the patients prior to their vascular surgery. How
have you used the conclusions from your data in pre-operative
evaluation of your vascular patients since completion of the study
in 2006?
Dr Schouten. Well, in the last 18 months the DECRESASE
VI study is enrolling patients. And what we do in that study is that
we have stratify patients into low-risk patients, intermediate and
high-risk patients. Patients at high risk all will undergo preopera-
tive cardiac stress testing. Patients at intermediate risk or at low risk
will undergo preoperative stress testing if the NT-proBNP level is
increased.
From the DECRESASE II study we know that patients at inter-
mediate risk, so one or two risk factors, in fact don’t really need to becardiac stress tested preoperatively if they are on beta-blockers and
tight heart rate control since the chance of finding patients with
extensive stress inducible myocardial ischemia is very low. But there
are some patients who have just one or two risk factors and still
develop postoperative cardiac events. We want to find out if we can
figure out which patients will develop cardiac events in these interme-
diate group patients by measuring NT-proBNP. If NT-proBNP is
elevated and turns out to be a good riskmarkerwe can then selectively
perform preoperative cardiac stress testing in these patients. Depend-
ing on the outcome of these stress tests, we then can address and if
necessary adjust perioperative management accordingly.
Dr A. Sidawy (Washington, DC). Did you attempt to corre-
late your results to clinical criteria that have been shown to influ-
ence cardiac complications?
Dr Schouten. We used the cardiac risk score which was
described by Eric Boersma from our group, which was in the
JAMA paper of 2001.
